InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights:
- InMed increased the yield of their proprietary IntegraSyn™ rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial scale production.
- InMed's rare cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields, further validating the IntegraSyn™ manufacturing approach as a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids.
- InMed announced a non-binding letter of intent to acquire BayMedica, a private company based in
Nevadaand Californiathat specializes in the manufacture and commercialization of rare cannabinoids.
- InMed has filed clinical trial applications in several countries as part of a Phase 2 Clinical Trial to evaluate INM-755 (cannabinol) cream for the treatment of Epidermolysis Bullosa.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor Conferences is part of
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: presenting present live at the Virtual Investor Conferences on
View original content to download multimedia:https://www.prnewswire.com/news-releases/inmed-pharmaceuticals-to-webcast-live-at-virtualinvestorconferencescom-september-8th-301370678.html
CONTACTS: InMed Pharmaceuticals, Colin Clancy, Senior Director, Investor Relations, +1 604 416 0999, email@example.com; Virtual Investor Conferences, John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, firstname.lastname@example.org